- Stocks
- Healthcare
- NASDAQ: CORT

Price (delayed)

$17.59

Market cap

$2.04B

P/E Ratio

20.94

Dividend/share

N/A

EPS

$0.84

Enterprise value

$1.95B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®

Corcept Therapeutics's debt has shrunk by 56% YoY and by 25% QoQ

The P/E is 33% less than the 5-year quarterly average of 31.2 and 17% less than the last 4 quarters average of 25.2

The EPS has declined by 15% year-on-year and by 2.3% since the previous quarter

The quick ratio is down by 14% year-on-year and by 10% since the previous quarter

What are the main financial stats of CORT

Market
Valuations
Earnings

Shares outstanding

115.93M

Market cap

$2.04B

Enterprise value

$1.95B

Price to earnings (P/E)

20.94

Price to book (P/B)

3.93

Price to sales (P/S)

5.96

EV/EBIT

18.21

EV/EBITDA

17.78

EV/Sales

5.67

Revenue

$343.09M

EBIT

$106.81M

EBITDA

$109.44M

Free cash flow

$133.88M

Per share
Balance sheet
Liquidity

EPS

$0.84

Free cash flow per share

$1.15

Book value per share

$4.48

Revenue per share

$2.95

TBVPS

$4.89

Total assets

$568.48M

Total liabilities

$45.81M

Debt

$1.56M

Equity

$522.68M

Working capital

$365.87M

Debt to equity

0

Current ratio

9.06

Quick ratio

8.76

Net debt/EBITDA

-0.86

Margins
Efficiency
Dividend

EBITDA margin

31.9%

Gross margin

98.5%

Net margin

28.4%

Operating margin

31.1%

Return on assets

17.5%

Return on equity

19.1%

Return on invested capital

23.7%

Return on capital employed

20.4%

Return on sales

31.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Corcept Therapeutics stock price performed over time

Intraday

-1.9%

1 week

-9.7%

1 month

-14.78%

1 year

-1.18%

YTD

-32.76%

QTD

-10.62%

How have Corcept Therapeutics's revenue and profit performed over time

Revenue

$343.09M

Gross profit

$337.97M

Operating income

$106.81M

Net income

$97.61M

Gross margin

98.5%

Net margin

28.4%

Corcept Therapeutics's operating income has decreased by 24% YoY and by 3% from the previous quarter

The operating margin has contracted by 22% YoY and by 4% from the previous quarter

CORT's net income is down by 14% YoY

Corcept Therapeutics's net margin has decreased by 13% YoY and by 2.7% QoQ

What is Corcept Therapeutics's growth rate over time

What is Corcept Therapeutics stock price valuation

P/E

20.94

P/B

3.93

P/S

5.96

EV/EBIT

18.21

EV/EBITDA

17.78

EV/Sales

5.67

The P/E is 33% less than the 5-year quarterly average of 31.2 and 17% less than the last 4 quarters average of 25.2

The EPS has declined by 15% year-on-year and by 2.3% since the previous quarter

The stock's price to book (P/B) is 57% less than its 5-year quarterly average of 9.2 and 23% less than its last 4 quarters average of 5.1

The company's equity rose by 15% YoY and by 2.3% QoQ

CORT's P/S is 27% below its 5-year quarterly average of 8.2 and 21% below its last 4 quarters average of 7.5

The revenue has declined by 2.3% year-on-year

How efficient is Corcept Therapeutics business performance

CORT's ROIC is down by 43% year-on-year and by 4.4% since the previous quarter

The return on equity has declined by 34% year-on-year and by 5% since the previous quarter

CORT's return on assets is down by 34% year-on-year and by 4.9% since the previous quarter

The return on sales has declined by 22% year-on-year and by 4% since the previous quarter

What is CORT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CORT.

How did Corcept Therapeutics financials performed over time

The quick ratio is down by 14% year-on-year and by 10% since the previous quarter

The company's total assets rose by 14% YoY and by 2.9% QoQ

Corcept Therapeutics's debt is 100% lower than its equity

CORT's debt to equity has shrunk by 100% YoY

Corcept Therapeutics's debt has shrunk by 56% YoY and by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.